Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 12, 2023 07:00 ET | Source: Genmab A/S

Genmab to Hold 2023 R&D Update and ASH Data Review Meeting

Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 12, 2023 – Genmab A/S (Nasdaq: GMAB) will hold its 2023 R&D Update and...
December 09, 2023 12:00 ET | Source: Genmab A/S

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)

Media Release COPENHAGEN, Denmark; December 9, 2023 Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67...
December 05, 2023 17:26 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; December 5, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 7,054 shares as a consequence of the exercise of employee warrants. The...
November 27, 2023 07:00 ET | Source: Genmab A/S

Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Media ReleaseCOPENHAGEN, Denmark; November 27, 2023 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation (BTD) for epcoritamab-bysp for the treatment of relapsed or...
November 21, 2023 16:45 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; November 21, 2023 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
November 21, 2023 16:42 ET | Source: Genmab A/S

Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; November 21, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 10,541 restricted stock units to members of the Board of...
November 09, 2023 09:14 ET | Source: Genmab A/S

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; November 9, 2023 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
November 09, 2023 05:00 ET | Source: Genmab A/S

Genmab to Present at Jefferies London Healthcare Conference

Media Release COPENHAGEN, Denmark; November 9, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer, Jan van de Winkel, Ph.D. and Chief Financial Officer, Anthony Pagano...
November 08, 2023 11:09 ET | Source: Genmab A/S

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; November 8, 2023 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
November 07, 2023 11:01 ET | Source: Genmab A/S

Genmab Announces Financial Results for the First Nine Months of 2023

November 7, 2023 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2023 Highlights Epcoritamab (TEPKINLY®) was granted conditional marketing authorization by the...